How Danaher Pays
Danaher's D1 to D10 normalized professional and leadership ladder priced across 34 markets, stock options, restricted stock units and relative-TSR performance shares from a 155.4 million share omnibus plan, a $23.80M CEO package at 343:1, and two located parent-entity H-1B wage records.
Band Hierarchy
Danaher publishes no enterprise-wide numeric grade ladder, and its operating companies retain the titles and salary structures they arrived with. D1 through D10 is an analytical normalization anchored on Washington, DC, built from official job postings and public salary records. Only the named executive officers and the board carry a company disclosure.
Professional and technical ladder — D1 through D6
Leadership ladder — D7 through D10
Disclosed executive layer
Track divergence
Hierarchy qualifications and legacy structures
- Danaher is a federation of operating companies. Cytiva, Beckman Coulter, Cepheid, Leica Biosystems, Pall, Radiometer, SCIEX, IDT and the newly acquired Masimo each carry legacy titles, salary structures and benefit arrangements from before they were acquired, and the public record does not establish that a universal grade harmonization has ever been completed.
- Because of that, the useful comparison unit at Danaher is role scope, business scale, technical scarcity and geography, mapped in that order, with title last. Two people with identical titles at two operating companies can sit two normalized levels apart.
- The D1 to D10 labels in this report are an analytical comparison layer. They are not Danaher's human resources information system, not a payroll grade and not something to quote in a negotiation.
- The one place Danaher does publish ranges is its own current job postings, which is why D7 and D8 are the only rows in this model classed as official: $160,000 to $250,000 base for sampled director roles and $180,000 to $300,000 for sampled senior director roles.
- The 2023 Veralto separation removed roughly 18,000 associates from the reported base and the June 2026 Masimo acquisition added a new population, so historical band or headcount comparisons across those events are not like-for-like.
- Named executive officers are corporate roles reported in United States dollars for the parent company. They are excluded from the band table entirely so that no city factor is ever applied to a global corporate package.
Peer-level mapping
| Band | Archetype | Peer mapping | Caveat |
|---|---|---|---|
| D1 | Trainee / Production Associate | Entry manufacturing and laboratory support at Thermo Fisher, Agilent or Abbott; apprentice and trainee grades in European operating companies | Operating-company titles at this level are set locally and by collective agreement in several European sites, so a like-named role can sit a level either side.Washington, DC anchor: the modeled US curve median of $55,000 base times the 1.04 headquarters city adjustment. |
| D2 | Associate / Engineer I / Scientist I | Graduate engineer and associate scientist grades across large-cap life-sciences instrumentation and diagnostics | First-line supervision and individual-contributor work overlap here, so people responsibility is not a reliable level signal.Anchored on the $79,000 US curve median with the 1.04 headquarters adjustment; no recurring equity grant is evidenced at this level. |
| D3 | Engineer II / Scientist II / Analyst | Engineer II and Scientist II tiers at Thermo Fisher, Agilent, Abbott and Stryker; the first level where scarce technical skills reset pay | Scientific disciplines run separate technical ladders inside the operating companies, so a bench scientist and a software engineer at the same normalized level can sit far apart on cash.Cross-checked against observed US anchors of $120,000 median for software engineer, $115,000 for mechanical engineer and $132,000 for scientist. |
| D4 | Senior Engineer / Senior Scientist | Senior engineer and senior scientist grades at Thermo Fisher, Agilent and Abbott; the deepest level of the external hiring market Danaher competes in | Public samples at this level mix base-only and total-pay submissions, so third-party medians read high for base and low for total.Anchored on the $130,000 US curve median; observed senior scientist median is $160,000 and observed product manager median $160,000 in the same market. |
| D5 | Lead / Staff / Principal / Manager | Staff and principal individual contributors and first-line managers across large-cap medtech and life-sciences instrumentation | Manager here can mean people, product or programme leadership, and a Danaher Business System leader carries no direct external equivalent.First level with any evidenced equity practice; disclosed selective grants run $5,000 to $20,000 a year and the equity figure shown is the residual that reconciles the modeled total. |
| D6 | Senior Manager / Principal Architect | Senior manager and principal architect tiers; roughly the level at which peers begin routine annual long-term incentive grants | Operating-company scale matters more than title here: a site-function leader at Cepheid and one at Cytiva can differ by a full level of scope.Cross-checked against the observed $173,000 median engineering manager and $225,000 median solution architect packages in the United States. |
| D7 | Director / Site Leader | Director and site general manager tiers at Thermo Fisher, Abbott, Stryker and Agilent | Scope, site size and revenue responsibility govern this level; the title alone is close to meaningless across a federation of operating companies.The best-evidenced level in the model: Danaher's own current postings show a $160,000 to $250,000 director base range, and observed director total pay medians $330,000. |
| D8 | Senior Director / Global Function Leader | Senior director and global function head tiers; the level at which annual long-term incentive becomes an expected part of a competitive offer | Rare enterprise technical fellows map alongside management at this level without equivalent people scope, and their cash mix differs.Danaher's own current postings show a $180,000 to $300,000 senior director base range; the disclosed selective grant band is $250,000 to $750,000. |
| D9 | Vice President / Operating-Company GM | Business-unit president and divisional vice president tiers at diversified medtech and life-sciences groups | An operating-company president can carry more revenue and more pay than a conventional functional vice president at the parent, so this row spans a wide real range.No Danaher disclosure exists below the named-officer group; this row bridges observed director benchmarks and proxy-disclosed executive pay. |
| D10 | Senior Vice President / Group Executive | Segment and platform president tiers sitting directly below the named corporate officers | Only individuals who qualify as named executive officers appear in the proxy tables, so this row is a scope benchmark and not a person-level package.Calibrated against the bottom of the 2025 named-officer range, where José-Carlos Gutiérrez-Ramos as SVP and Chief Science Officer reported $6,243,771 total. |
Critical evidence warning
Danaher does not publish salary bands, band minimums, band midpoints, a nonexecutive equity-grant matrix, an enterprise rating scale or a merit matrix, and its operating companies set much of their own pay. Every non-executive figure in this report is therefore either a third-party observation, an official job posting for a specific sampled role, or a transparent model built on one of those. Public salary evidence is strongest for the United States and India, moderate for the United Kingdom, Germany and Australia, and genuinely sparse for Japan, Sweden, Switzerland, Singapore, New Zealand and the United Arab Emirates. Treat the sparse markets as planning envelopes pending local validation, not as benchmarks.
Compensation by Band — Washington, DC
Low / median / high annual values at 1.00× base and 1.00× total-compensation factors versus Washington, DC. Total equals base plus bonus plus annualized equity.
| Band | Title | Base | Variable | Total TC | Equity |
|---|---|---|---|---|---|
| D1 | Trainee / Production Associate 0–2 years · modeled | $49K – $66K | 3% | $59K $50K – $68K | — |
| D2 | Associate / Engineer I / Scientist I 0–3 years · modeled | $70K – $94K | 6% | $87K $74K – $100K | — |
| D3 | Engineer II / Scientist II / Analyst 2–5 years · reported | $91K – $124K | 8% | $116K $99K – $134K | — |
| D4 | Senior Engineer / Senior Scientist 4–8 years · reported | $115K – $155K | 10% | $149K $126K – $171K | — |
| D5 | Lead / Staff / Principal / Manager 6–10 years · modeled | $135K – $182K | 13% | $195K $166K – $224K | $16K |
| D6 | Senior Manager / Principal Architect 8–13 years · modeled | $159K – $215K | 18% | $247K $210K – $284K | $26K |
| D7 | Director / Site Leader 10–16 years · verified | $190K – $257K | 28% | $341K $290K – $392K | $54K |
| D8 | Senior Director / Global Function Leader 14–20 years · verified | $239K – $323K | 40% | $499K $424K – $574K | $106K |
| D9 | Vice President / Operating-Company GM 16–24 years · modeled | $309K – $419K | 65% | $1.04M $884K – $1.20M | $439K |
| D10 | Senior Vice President / Group Executive 20+ years · modeled | $486K – $658K | 95% | $3.22M $2.74M – $3.71M | $2.11M |
Total Compensation Range by Band
Total compensation in Washington, DC across the employee bands. Ranges are planning envelopes around the median, not offer bands.
Global Footprint & Pay Arbitrage
Danaher disclosed roughly 22,000 associates in North America, 20,000 in Western Europe, 3,000 in other developed markets and 15,000 in high-growth markets at the end of 2025, and no city-level headcount anywhere. Washington, DC is the pay anchor; every other market is calibrated against it by a country seniority curve multiplied by a city adjustment.
Office and market catalogue — calibration factors versus Washington, DC
| Location | Likely office profile | Presence | Base | TC |
|---|---|---|---|---|
Washington, DC United States · USD | Corporate headquarters; corporate leadership, finance and client-facing roles | Disclosed principal executive office | 1.00× | 1.00× |
Marlborough United States · USD | Life-sciences and diagnostics hub in the Boston corridor | Operating-company footprint | 1.02× | 1.02× |
Sunnyvale United States · USD | Highest-cost engineering and R&D market in the footprint, led by Cepheid | Operating-company footprint | 1.14× | 1.14× |
Brea United States · USD | Diagnostics hub anchored on Beckman Coulter | Operating-company footprint | 1.06× | 1.06× |
Indianapolis United States · USD | Operations, commercial and technical roles at the low end of the US cost range | Operating-company footprint | 0.89× | 0.89× |
Miami United States · USD | Commercial and Latin America regional roles | Operating-company footprint | 0.93× | 0.93× |
Chaska United States · USD | Diagnostics manufacturing and operations hub | Operating-company footprint | 0.90× | 0.90× |
Boston United States · USD | Life-sciences and R&D market with the deepest external talent competition | Operating-company footprint | 1.04× | 1.04× |
Bangalore India · INR | Technology, engineering and shared-services hub; the deepest India evidence base | Operating-company footprint | 0.13× | 0.13× |
Mumbai India · INR | Commercial, finance and India regional leadership | Operating-company footprint | 0.14× | 0.14× |
Gurgaon India · INR | Commercial, technology and corporate-services roles | Operating-company footprint | 0.13× | 0.13× |
Amersham United Kingdom · GBP | Cytiva life-sciences operating hub outside London | Operating-company footprint | 0.59× | 0.59× |
Cardiff United Kingdom · GBP | Operations and technical roles at the lowest UK city adjustment in the model | Operating-company footprint | 0.51× | 0.51× |
London United Kingdom · GBP | Regional leadership and commercial hub | Operating-company footprint | 0.66× | 0.66× |
Sydney Australia · AUD | Australia and New Zealand commercial and leadership hub | Operating-company footprint | 0.71× | 0.71× |
Melbourne Australia · AUD | Commercial, technical and field-service hub | Operating-company footprint | 0.67× | 0.67× |
Auckland New Zealand · NZD | Supplemental market with no Danaher-specific salary observation located | Regional coverage | 0.60× | 0.60× |
Wetzlar Germany · EUR | Leica-related optics engineering and manufacturing hub | Operating-company footprint | 0.54× | 0.54× |
Munich Germany · EUR | Highest-cost German commercial and technical market in the footprint | Operating-company footprint | 0.66× | 0.66× |
Mannheim Germany · EUR | Operations and commercial roles in the Rhine-Neckar cluster | Operating-company footprint | 0.57× | 0.57× |
Paris France · EUR | Supplemental European commercial market | Regional coverage | 0.61× | 0.61× |
Milan Italy · EUR | Supplemental European commercial market with the widest junior-to-senior spread in Europe | Regional coverage | 0.48× | 0.48× |
Copenhagen Denmark · DKK | Nordic commercial and technical market | Regional coverage | 0.63× | 0.63× |
Uppsala Sweden · SEK | Cytiva life-sciences R&D and bioprocess manufacturing hub | Operating-company footprint | 0.56× | 0.56× |
Zug Switzerland · CHF | The only market in the model that exceeds the US anchor at senior levels | Regional coverage | 0.99× | 0.99× |
Basel Switzerland · CHF | Life-sciences commercial and technical market | Regional coverage | 0.91× | 0.91× |
Shanghai China · CNY | Largest China commercial, strategy and engineering hub | Operating-company footprint | 0.27× | 0.27× |
Suzhou China · CNY | Manufacturing and engineering hub; the lowest junior factor in the model | Operating-company footprint | 0.22× | 0.22× |
Beijing China · CNY | Commercial, regulatory and government-facing roles | Operating-company footprint | 0.25× | 0.25× |
Singapore Singapore · SGD | Asia-Pacific commercial, technical and operations hub | Operating-company footprint | 0.48× | 0.48× |
Tokyo Japan · JPY | Japan commercial and regional roles; no Danaher-specific salary record located | Regional coverage | 0.41× | 0.41× |
Toronto Canada · CAD | Canadian commercial and technical hub | Operating-company footprint | 0.69× | 0.69× |
Vancouver Canada · CAD | Higher-cost Canadian technical and commercial market | Regional coverage | 0.73× | 0.73× |
Dubai United Arab Emirates · AED | Middle East regional commercial hub; thinnest evidence base in the model | Regional coverage | 0.48× | 0.48× |
Danaher discloses no employee count by city or by named office, so this catalogue ranks nothing by headcount. Each location is classified by the business footprint the operating companies actually run there, and markets where no Danaher-specific salary observation was located are marked as regional coverage rather than given an invented office weight.
Washington, DC anchor medians — the basis of every modeled cell
| Band | Base | Stock | Bonus | Total |
|---|---|---|---|---|
| D3 | $108K | $0 | $9K | $116K |
| D4 | $135K | $0 | $14K | $149K |
| D7 | $224K | $54K | $63K | $341K |
| D8 | $281K | $106K | $112K | $499K |
- The Washington, DC column is the anchor and carries a 1.04 city adjustment over the modeled United States national curve, so the headquarters premium is already inside every anchor number shown.
- United States anchors are cross-checked against multiple public salary platforms and against Danaher's own current postings, which is why the director and senior director rows carry an official evidence class and the rest do not.
- India runs from about 12.5 percent of the anchor at D1 to about 28.8 percent at D10 in Bangalore, so the gap narrows from roughly eight times at entry to about three and a half times at group-executive level.
- China shows the steepest compression in the model, from 22 to 27 percent of the anchor at D1 across Suzhou, Beijing and Shanghai to 49 to 58 percent at D10, reflecting how much more globally contested senior Chinese commercial and engineering talent is.
- Zug is the only market that exceeds the United States anchor, reaching 1.12 times at D10, and Basel reaches 1.04 times. Both sit on thin Danaher-specific evidence and should be treated as directional.
- Named executive officer packages are global corporate figures reported in United States dollars. They are deliberately absent from the band table so that no location factor is ever applied to them.
Model rules
- Every modeled cell is the Washington, DC anchor median multiplied by a location factor and then by the 27 August 2026 frozen foreign-exchange snapshot. The rates are not live and use no purchasing-power-parity adjustment.
- Location factors are level-dependent outside the United States. Each non-US market carries a junior factor at D1 and a senior factor at D10, interpolated linearly across the ladder between them. United States cities carry a single flat factor because the source calibration applies one city adjustment across the whole curve.
- A total compensation cell is base plus target variable plus annualized equity. The source model also loaded a notional employer benefit cost into its total figures; that loading has been stripped here so that the components reconcile to the total on every row.
- At D5 and above the equity component shown is the residual that reconciles the modeled total, not the midpoint of the disclosed selective grant range. The two diverge at D7 and above because the grant ranges describe what a recipient gets while the total median describes the whole band, most of whom receive nothing.
- Sign-on payments, relocation, expatriate premiums, per diem, temporary-assignment allowances and one-time retention awards are all excluded. So are employer taxes and severance.
- Danaher is not an information-technology delivery business, so there is no onsite-versus-offshore rate card. India, China and the other lower-cost markets contain engineering, R&D, manufacturing, shared services and commercial roles, and equivalent-scope country curves are the defensible comparison.
Variable Pay & Annual Cash Incentive
Danaher discloses its named-executive annual cash incentive in detail and discloses nothing about the nonexecutive bonus grid. The band targets below are modeled from the source curve; the executive formula, weightings and payout history are company disclosures.
| Band | Target | Mechanism | Recent payout |
|---|---|---|---|
D1 Trainee / Production Associate | 0% to 5% of base | Local annual incentive where the operating company runs one; several sites at this level have no scheme at all. | Not publicly disclosed |
D2 Associate / Engineer I / Scientist I | 3% to 8% of base | Local annual incentive administered by the operating company. | Not publicly disclosed |
D3 Engineer II / Scientist II / Analyst | 5% to 10% of base | Local annual incentive administered by the operating company. | Not publicly disclosed |
D4 Senior Engineer / Senior Scientist | 8% to 12% of base | Local annual incentive administered by the operating company. | Not publicly disclosed |
D5 Lead / Staff / Principal / Manager | 10% to 15% of base | Annual target incentive on operating-company results; a sales commission plan supersedes it for quota-carrying roles. | Not publicly disclosed |
D6 Senior Manager / Principal Architect | 15% to 20% of base | Annual target incentive on operating-company results; a sales plan supersedes it for quota-carrying roles. | Not publicly disclosed |
D7 Director / Site Leader | 20% to 35% of base | Annual target incentive weighted to site or function performance; the spread within the band is wide. | Not publicly disclosed |
D8 Senior Director / Global Function Leader | 30% to 50% of base | Annual target incentive weighted to global function or platform performance. | Not publicly disclosed |
D9 Vice President / Operating-Company GM | 50% to 80% of base | Annual target incentive dominated by the profit-and-loss result of the business the person runs. | Not publicly disclosed |
D10 Senior Vice President / Group Executive | 75% to 115% of base | Annual target incentive on segment or platform performance. | Not publicly disclosed |
Officer Executive Vice President / Corporate Officer | 115% to 125% of base | Annual executive cash incentive, 60 percent company and 40 percent personal for 2023 to 2025, moving to 70 percent company and 30 percent personal for 2026. | 2025 company component 133 percent; 2024 110 percent; 2023 93 percent |
CEO President and Chief Executive Officer | 200% of base | Annual executive cash incentive on the same company and personal split, with the personal half assessed against objectives and the four Core Behaviours. | 2025 composite 149.8 percent; 2024 122.0 percent; 2023 121.8 percent, each applying the disclosed 60/40 weighting |
Executive incentive targets — percent of salary
Named-executive outcomes
| Executive | Target | Paid | Attainment |
|---|---|---|---|
| Rainer M. Blair | $2,800,000 | $4,194,400 | 149.8% of target |
| Matthew R. McGrew | $1,256,663 | $1,882,480 | 149.8% of target |
| Christopher P. Riley | $1,060,000 | $1,587,880 | 149.8% of target |
| Julie Sawyer Montgomery | $1,060,000 | $1,587,880 | 149.8% of target |
| José-Carlos Gutiérrez-Ramos | $1,021,729 | $1,530,550 | 149.8% of target |
Employee payout timing and history
Danaher publishes no bonus-target grid by level, no nonexecutive payout history and no companywide funding rule. Cadence, plan design and even the existence of a scheme vary by operating company and by country, so the D1 to D10 targets shown here are modeled ranges rather than a Danaher schedule. The 133 percent company component is an executive-plan factor and should not be read as a companywide multiplier.
Sales and special incentives
Quota-carrying commercial roles across the operating companies run their own commission plans that can carry materially more leverage than the generic band targets, and no global sales schedule, accelerator table or draw arrangement was located in any public source. A seller's on-target earnings will be understated by the band targets in this report.
Equity — RSUs, PSUs, Options & ESPP
Danaher is a United States issuer running one broad omnibus plan plus two deferred-compensation vehicles. Unusually for a company of this size, stock options remain a material instrument rather than a legacy one, and no broad-based employee stock purchase plan is disclosed in any source reviewed for this report.
- Simple utilisation before the refresh was 68.6 percent: 135,443,592 authorized against 42,512,110 available, implying 92,931,482 shares used or committed. The same used amount is 59.8 percent of the post-refresh authorization.
- Options dominate the outstanding award mix. 13,248,862 options were outstanding at 31 January 2026 at a $178.38 weighted-average exercise price with 5.2 years of weighted-average remaining term, against only 3,262,598 outstanding full-value awards.
- Burn rate is low for the sector at 0.42 percent for 2025 and 0.43 percent on a three-year average, which is consistent with equity being concentrated in leadership rather than spread across 60,000 associates.
- Overhang was 8.30 percent before the amendment and 10.60 percent pro forma after it. The step up is the direct cost of the 20 million share refresh to existing holders.
- With a $178.38 average strike against a $216.60 reference price, the outstanding option book was in the money at the research cut-off, but the August 2026 special awards were struck at $195 and vest only in years four and five.
Equity plan capacity and instrument mix
Vesting — common reported employee schedule
Post-2021 employee option and restricted stock unit awards generally vest pro rata over four years, and the individual award agreement controls. Performance share units add a performance condition plus a service and holding requirement, and the 2023 to 2025 cycle carries a further holding period through 2027 on top of the three-year performance period. The August 2026 special leadership options break this pattern entirely: they vest 50 percent at year four and 50 percent at year five, which is a retention structure rather than a reward structure.
Eligibility by hierarchy level
- Legal eligibility and economic practice are different things here. The plan makes all employees, nonemployee directors and consultants eligible, but no recurring grant practice is publicly evidenced below the lead, staff and manager level.
- From D5 to D7 the disclosed picture is selective critical-talent, new-hire and retention grants running roughly $5,000 to $250,000 a year, awarded at the operating company's discretion rather than by an entitlement matrix. Cadence is not disclosed.
- From D8 upward an annual long-term incentive becomes an expected component of a competitive package, with disclosed ranges of roughly $250,000 to $750,000 at senior director, $750,000 to $2 million at vice president and $1.5 million to $5 million at group executive.
- At $216.60 a share those ranges correspond to roughly 24 to 92 shares a year at D5, 347 to 1,154 at D7, 3,463 to 9,233 at D9 and 6,926 to 23,084 at D10. Share counts are illustrative and are not option fair values.
- Danaher publishes no minimum eligible level, no standard grant table and no guarantee that any individual employee receives a grant, so a candidate below senior director should treat equity as negotiable rather than assumed.
Indicative annual grant value by band — Washington, DC
| Band | Annual value (USD) | Median | Shares at $216.6 |
|---|---|---|---|
| D5 | $12K – $20K | $16K | ~55–91 |
| D6 | $20K – $33K | $26K | ~90–151 |
| D7 | $41K – $68K | $54K | ~188–314 |
| D8 | $80K – $133K | $106K | ~367–612 |
| D9 | $330K – $549K | $439K | ~1,521–2,536 |
| D10 | $1.58M – $2.64M | $2.11M | ~7,301–12,169 |
Annualized planning value (±25%), not the face value of every new-hire grant. Share equivalents use the $216.6 reference price at 27 August 2026 reference quote and ignore plan valuation rules and PSU performance. Highlighted rows are disclosed grant-date stock awards.
Named executive target equity
| Executive | Target | Units / structure |
|---|---|---|
Rainer M. Blair President and Chief Executive Officer | $17.68M 2025 grant-date equity | $9,292,370 of stock awards and $8,386,657 of option awards, an almost even split between full-value and appreciation instruments. The 2026 performance share design is 50 percent relative total shareholder return against the S&P 500 Healthcare index and 50 percent adjusted earnings per share. |
Matthew R. McGrew Executive Vice President and Chief Financial Officer | $4.79M 2025 grant-date equity | $2,519,058 of stock awards and $2,273,537 of option awards. He was succeeded by Matthew Gugino, who received a $12.5 million special option award on 4 August 2026 struck at $195. |
Christopher P. Riley Executive Vice President, Biotechnology | $8.72M 2025 grant-date equity | $4,425,309 of stock awards and $4,294,467 of option awards, plus a separate 41,072 unit restricted stock unit award worth $8 million granted on 4 August 2026 vesting half at 18 months and half at 30 months. |
Julie Sawyer Montgomery Executive Vice President, Diagnostics and incoming Chief Executive Officer | $8.72M 2025 grant-date equity | Identical 2025 recurring grant to the Biotechnology platform. Her incoming package adds a $13.2 million recurring 2027 long-term incentive target and a one-time 245,701 option award valued at $20 million, struck at $195 and vesting half at year four and half at year five. |
José-Carlos Gutiérrez-Ramos Senior Vice President and Chief Science Officer | $3.73M 2025 grant-date equity | $1,959,422 of stock awards and $1,768,323 of option awards, the smallest named-officer grant, plus a 13,477 unit restricted stock unit award worth $2,625,000 on 4 August 2026 vesting in full at 12 months. |
Executive Compensation
2025 Summary Compensation Table values from the 2026 proxy statement filed on 25 March 2026. Stock and option figures are grant-date accounting values rather than money received, and the 25 percent settlement on the 2023 to 2025 performance share cycle shows how far the two can diverge.
Reading the package
Salary was 5.9 percent of the chief executive's 2025 reported total, the annual cash incentive 17.6 percent and equity 74.3 percent, split almost evenly between $9.29 million of stock awards and $8.39 million of option awards. That option weighting is the distinguishing feature of Danaher executive pay: most large-cap peers have moved almost entirely to full-value awards, while Danaher still delivers close to half of its chief executive's long-term incentive in instruments that are worth nothing unless the share price rises above the strike.
Danaher's 2025 chief executive pay sits just below Abbott and above Stryker and Agilent. Thermo Fisher's year includes a large retention award and is not a clean recurring comparator, so reading Danaher as paying a third of Thermo Fisher would be wrong. All five figures are grant-date accounting values and none of them equals realized pay.
Named Executive Officers & Board
Danaher is in the middle of a chief executive transition. Julie Sawyer Montgomery, most recently Executive Vice President for Diagnostics, is scheduled to become President and Chief Executive Officer on 1 October 2026, and Rainer Blair transitions out. A new Chief Financial Officer, Matthew Gugino, also received a special award in the same August 2026 filing.
Julie Sawyer Montgomery's incoming terms are a $1.5 million base salary, a 200 percent target annual cash incentive worth $3 million at target, and a $13.2 million recurring long-term incentive target for 2027, alongside a one-time $20 million option award granted on 4 August 2026. That special award covers 245,701 options struck at $195 with a ten-year term, vesting 50 percent at year four and 50 percent at year five, so none of it is realisable before 2030. Matthew Gugino received a parallel $12.5 million option award covering 153,563 options on the same terms.
Board compensation framework
| Element | Amount | Notes |
|---|---|---|
| Annual cash retainer | $130,000 | Reported at the start of 2025 for each nonemployee director. |
| Annual equity target | $220,000 | Delivered as a mix of options and restricted stock units. |
| Lead independent director | $42,500 | Additional retainer under the 2026 policy. |
| Audit Committee chair | $30,000 | Additional retainer under the 2026 policy, the largest committee premium. |
| Other committee chairs | $25,000 | Additional retainer under the 2026 policy. |
| Excess meeting fee | $2,000 | Payable per meeting beyond 20 in a year. |
The standard director package of a $130,000 cash retainer plus a $220,000 equity target is unremarkable. What is not standard is the August 2026 grant of 1,000,000 options and 500,000 restricted stock units to each of Steven M. Rales as Chairman and Mitchell P. Rales as Executive Committee Chair, disclosed by unit count without a summarised grant value. Those awards are on a different scale to ordinary director compensation and should be read as founder and control-related retention rather than as board pay.
Regional heads and other officers
Most operating-company presidents, regional heads, the chief human resources officer, the general counsel and the rest of the senior layer are not individually disclosed because they are neither named executive officers nor reportable insiders. For a company that runs its businesses through semi-autonomous operating companies, that is a large gap: the people who actually set pay for most of the 60,000 associates are invisible in the filings. The D9 and D10 rows in this report should be used as role-scope benchmarks rather than as a substitute for person-level packages that do not exist publicly.
Insider Trades — SEC Forms 3/4/5
Danaher is a New York Stock Exchange issuer, so the governing record is SEC Forms 3, 4 and 5 and Rule 144 notices. BSE and NSE filings, SEBI substantial-acquisition rules, Indian promoter-group disclosure and ASX substantial-holder notices are not applicable to the listed parent. Compensation grants below are separated from open-market sales so that awards are never counted as investment activity.
| Date | Person | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-21 | Rainer M. Blair President and Chief Executive Officer | Sale Largest of three same-day tranches from trust-held shares. | 39,193 | $218.73 | $8.57M |
| 2026-08-21 | Rainer M. Blair President and Chief Executive Officer | Sale Second tranche of the same 21 August 2026 disposal. | 11,307 | $217.77 | $2.46M |
| 2026-08-21 | Rainer M. Blair President and Chief Executive Officer | Sale Third tranche; the three lots total 58,255 shares for about $12.74 million. | 7,755 | $219.35 | $1.70M |
| 2026-08-04 | Julie Sawyer Montgomery Incoming President and Chief Executive Officer | Award One-time nonqualified option award struck at $195, vesting 50 percent at year four and 50 percent at year five, ten-year term. | 245,701 | $195.00 | $20.00M |
| 2026-08-04 | Matthew Gugino Executive Vice President and Chief Financial Officer | Award One-time nonqualified option award on the same $195 strike and year four and five vesting terms. | 153,563 | $195.00 | $12.50M |
| 2026-08-04 | Christopher P. Riley Executive Vice President, Biotechnology | Award Restricted stock unit retention award vesting 50 percent at 18 months and 50 percent at 30 months. | 41,072 | — | $8.00M |
| 2026-08-04 | José-Carlos Gutiérrez-Ramos Senior Vice President and Chief Science Officer | Award Restricted stock unit retention award vesting in full at 12 months, the shortest cliff in the August 2026 set. | 13,477 | — | $2.63M |
| 2026-08-04 | Steven M. Rales Chairman of the Board | Award Nonqualified options struck at $195 vesting 50 percent at year four and 50 percent at year five. The filing disclosed the unit count without a summarised grant value, so no dollar figure is shown. | 1,000,000 | $195.00 | $0 |
| 2026-08-04 | Steven M. Rales Chairman of the Board | Award Restricted stock units granted alongside the option award; value not summarised in the filing. | 500,000 | — | $0 |
| 2026-08-04 | Mitchell P. Rales Chair of the Executive Committee | Award Nonqualified options on the same $195 strike and year four and five vesting; value not summarised in the filing. | 1,000,000 | $195.00 | $0 |
| 2026-08-04 | Mitchell P. Rales Chair of the Executive Committee | Award Restricted stock units granted alongside the option award; value not summarised in the filing. | 500,000 | — | $0 |
| 2024-08 | Rainer M. Blair President and Chief Executive Officer | Sale Older reference disposal retained at month-level precision, at a share price well above the 2026 level. | 9,007 | $280.00 | $2.52M |
Reading guide
Benefits & Perks
Danaher's benefit record is strong in exactly one place and thin everywhere else. The United States retirement plan is covered by an audited Form 11-K, so its terms are precise. Outside the United States the operating companies administer their own arrangements and the only reliably evidenced items are statutory floors, which are the legal minimum rather than what Danaher actually offers.
United States
- Retirement — 401(k) safe-harbor match of up to 4 percent. 100 percent of the first 3 percent of eligible pay plus 50 percent of the next 2 percent, immediately vested. Employee-reporting sites that show 5 percent are lower-confidence or specific to one operating company; the filed plan document governs. [official]
- Retirement — Discretionary retirement contribution of up to 4 percent. Up to 2 percent of eligible pay plus a further 2 percent on pay above the Social Security wage base once eligibility is met, generally vesting over three years. This is discretionary and is not guaranteed in any year. [official]
- Retirement — Deferrals up to 75 percent of eligible pay. Subject to tax-law limits. Plan assets were $7.085 billion at 31 December 2025 against $166.9 million of 2025 employer contributions, administered within a Fidelity recordkeeping ecosystem under the filed plan documents. [official]
- Health — Medical, mental-health and family-care programmes. Official careers materials describe medical options, mental-health support, family-care resources and wellbeing rewards. Carrier, plan tiers and the employee premium split are not centrally disclosed and vary by operating company. [official]
Global programs
- Learning — Danaher Business System and Danaher Go. Danaher emphasises DBS learning, the four Core Behaviours and deliberate internal talent movement through the Danaher Go mobility programme. Reimbursement limits, tuition caps and platform subscriptions are not centrally published. [official]
- Mobility — Internal movement across operating companies. Moving between operating companies is an explicit part of the talent model, which in practice is how an individual escapes a legacy salary structure inherited from an acquisition. No relocation, expatriate or assignment allowance schedule is disclosed. [official]
- Pay equity — Qualitative only. Danaher discusses inclusion and talent systems, but no quantitative global pay-equity audit, gender pay-gap regression or country pay-gap table was located in any source reviewed for this report. [npd]
- Review cycle — February for named executives only. Named executive salaries are typically reviewed in February under the proxy-disclosed process. No single global nonexecutive review month, effective date, mid-year correction policy or off-cycle calendar is disclosed, and operating companies can run country-specific cycles. [official]
Benefit fields not publicly quantified
Health-insurance carriers and premium splits in every country, Indian family-floater limits, global paid-time-off tables, parental-leave top-ups, National Pension System participation, company-car policy, meal, transport and mobile allowances, tuition caps, sabbatical arrangements and any enterprise-wide remote-work standard were not established consistently in any source. Because Danaher's operating companies administer benefits themselves, these gaps are structural rather than accidental, and a local offer letter and benefit summary are required for offer-level diligence.
Performance Review & Pay Progression
Danaher's disclosed performance philosophy rests on the four Core Behaviours, Apply Insights, Deliver Results, Win as a Team and Instill Trust, which are referenced directly in the personal-performance half of the executive incentive. Below the named executive officers, almost nothing about how performance converts into pay is public.
Not publicly disclosed
Modeled promotion planning timeline
| Band | Years to next scope | Promotion hike | Status |
|---|---|---|---|
| D1 | 1–3 years to D2 | Not disclosed | Modeled planning interval |
| D2 | 1–3 years to D3 | Not disclosed | Modeled planning interval |
| D3 | 2–4 years to D4 | Not disclosed | Modeled planning interval |
| D4 | 2–4 years to D5 | Not disclosed | Modeled planning interval |
| D5 | 3–5 years to D6 | Not disclosed | Modeled planning interval |
| D6 | 3–5 years to D7 | Not disclosed | Modeled planning interval |
| D7 | 3–6 years to D8 | Not disclosed | Modeled planning interval |
| D8 | 3–6 years to D9 | Not disclosed | Modeled planning interval |
| D9 | Opportunity and succession dependent | Not disclosed | Modeled planning interval |
| D10 | Opportunity and succession dependent | Not disclosed | Modeled planning interval |
The Core Behaviours are the one part of the framework with real visibility, because the proxy applies them to the personal half of the named-executive incentive. The 2026 shift from a 60/40 to a 70/30 company-to-personal weighting is therefore a genuine signal about how much individual assessment is expected to move pay at the top, and it moves in the direction of less. Whether that cascades below the officer group is not disclosed.
Pay progression evidence
Modeled progression, not Danaher policy: D1 to D2 and D2 to D3 typically take 1 to 3 years for an 8 to 15 percent base increase; D3 to D4 and D4 to D5 take 2 to 4 years for 8 to 15 percent; D5 to D6 and D6 to D7 take 3 to 5 years for 10 to 18 percent; D7 to D8 and D8 to D9 take 3 to 6 years for 12 to 25 percent; and everything above D9 depends on succession slots, operating-company scale and portfolio change rather than tenure, with the change usually arriving as an equity reset rather than a salary move. These are workforce-planning heuristics, not promises, and at Danaher the fastest real progression route is often a move to a different operating company rather than a promotion inside one.
H-1B / LCA Visa Footprint — United States
Danaher's visa record is the least usable dataset in this report, and the reason is structural. Labour condition applications are filed by the legal entity that employs the worker, so filings scatter across Cytiva, Leica Biosystems, Beckman Coulter and the other operating companies rather than accumulating under the parent. A search of the direct Danaher Corporation entity returns two records.
Dataset summary
| Dataset | Result | Interpretation |
|---|---|---|
| Direct Danaher Corporation legal entity | 2 located labour condition application records across 2021 and 2025 | The parent entity is largely a holding and corporate-services company, so a thin filing record is what you would expect rather than a data failure. |
| Cytiva entity filings | Average wages of about $119,164 in 2025, $133,489 in 2024 and $119,742 in 2023 | Averages published by aggregators without record-level detail; the 2024 to 2025 fall reflects role mix rather than a pay cut. |
| Leica Biosystems Richmond entity filings | Average wages of about $154,039 in 2025, $139,250 in 2024 and $131,667 in 2023 | The highest operating-company average located, rising in each of the three years. |
| Consolidated Danaher view | Not constructible from public aggregators | Combining entity-level averages of different sizes would produce a number with no defensible meaning, so no consolidated percentile is published here. |
City-level H-1B wage history
| City | P25 | Median | P75 | Records |
|---|---|---|---|---|
Fuquay-Varina, NC 2025 filing for a Senior Data and Analytics Administrator under the direct parent entity. | $165K | $165,000 | $165K | 1 |
Brea, CA 2021 filing for an Internal Audit Manager under the direct parent entity, at the Beckman Coulter diagnostics hub. | $128K | $128,366 | $128K | 1 |
Direct-parent aggregate Linear interpolation across the two located records; a descriptive statistic on a sample of two, not a distribution. | $138K | $146,683 | $156K | 2 |
All-years aggregates. P25/P75 are rounded reconstruction values marked modeled; medians and record counts are the stronger fields.
Selected title / worksite records
| Title | Worksite | Proffered wage | Notes |
|---|---|---|---|
| Senior Data and Analytics Administrator | Fuquay-Varina, North Carolina | $165,000 | 2025 filing; the higher of the two direct-parent records and a corporate-services rather than an R&D role. |
| Internal Audit Manager | Brea, California | $128,366 | 2021 filing; a corporate finance role sited at a diagnostics operating company. |
| Cytiva entity average | Multiple United States sites | About $119,164 in 2025 | Aggregator average across the Cytiva legal entity; role mix is not published. |
| Leica Biosystems Richmond entity average | Richmond, Illinois and related sites | About $154,039 in 2025 | Aggregator average across the Leica Biosystems Richmond legal entity. |
Reading the data correctly
- Labour condition application wages are base salary only. They exclude target incentive and any equity, so they must never be compared with a total compensation figure from this report.
- A proffered wage is what the employer attests it will pay at or above the prevailing wage for the role and area. It is not evidence of what an incumbent actually earns after merit increases.
- Two records cannot produce a percentile distribution. The 25th and 75th percentile figures shown are linear interpolations between two points and are published only to be transparent about the method.
- Operating-company entity averages cannot be pooled into a consolidated Danaher figure without record-level deduplication, which no public aggregator provides.
- No United States Citizenship and Immigration Services approval or denial counts were located for any Danaher entity, so no approval rate is stated anywhere in this report.
Key Nuances & Insights
Cytiva, Beckman Coulter, Cepheid, Leica Biosystems, Pall, Radiometer, SCIEX and now Masimo each arrived with their own titles, grades and benefit arrangements, and the public record does not establish that a universal grade harmonization was ever completed. A Danaher offer is really an offer from one of those businesses, which is why two identical titles can sit two levels apart and why no single company-wide pay statement is defensible.
Danaher's median employee earned $69,440 in 2025. That is what a global workforce of 60,000 looks like when it is weighted towards manufacturing, laboratory, field-service and operations roles across 16 countries. The chief executive package of $23.80 million is smaller than Abbott's and roughly a third of Thermo Fisher's; the ratio is high because the denominator is low.
13,248,862 options were outstanding at 31 January 2026 against only 3,262,598 full-value awards, and 47 percent of the chief executive's 2025 long-term incentive was option value. Most large-cap peers have moved almost entirely to restricted stock and performance shares. At Danaher a senior package can be worth nothing at all if the share price stalls, which is a materially different risk profile to an all-RSU offer.
The omnibus plan makes every employee, director and consultant eligible, and no recurring grant practice is evidenced below the lead, staff and manager level. Reading plan eligibility as an entitlement is the single most common misreading of Danaher's disclosures. Below senior director, equity is a negotiation item rather than a standard component.
No broad-based discounted share purchase plan appears anywhere in the reviewed sources. For a New York Stock Exchange issuer of this size that is unusual, and it removes the one equity component an ordinary employee can normally size for themselves. Anyone comparing a Danaher offer with a technology or large pharmaceutical package should price the missing purchase plan rather than assume it exists.
Relative total shareholder return over 2023 to 2025 was approximately 0.32 percent, below the 35th percentile of the comparison group, and only a positive-return floor produced any settlement at all. Earned shares then carry a holding period through 2027. Grant-date accounting values in the proxy are therefore a poor guide to what senior leaders actually received.
Each named officer's disclosed 2025 cash incentive equals their salary times their target percentage times 149.8 percent, to the dollar, across all five individuals. That implies a single uniform composite factor was applied rather than five differentiated personal outcomes at the payout stage, and it means the 40 percent personal weighting had less individual effect in 2025 than the design suggests.
Moving the executive incentive from 60 percent company and 40 percent personal to 70 percent company and 30 percent personal makes every officer's cash more sensitive to adjusted earnings per share, free-cash-flow conversion and core revenue growth, and less sensitive to their own year. The 2026 performance share design also switches the relative return comparison to the S&P 500 Healthcare index.
Suzhou runs at 22 percent of the Washington, DC anchor at entry level and 49 percent at group-executive level; Shanghai runs 27 to 58 percent. India moves from 12.5 to 28.8 percent in Bangalore. In every case the entry-level gap is a local labour-market gap while the senior gap is a global one, which is why the ratio more than doubles across the ladder.
Zug reaches 1.12 times the Washington, DC anchor at group-executive level and Basel 1.04 times, the only cells in the entire 34-market model that exceed the United States. Both sit on thin Danaher-specific evidence, so treat them as directional rather than as a relocation argument.
A $20 million option award to the incoming chief executive and a $12.5 million award to the incoming chief financial officer, both struck at $195 and vesting half at year four and half at year five, are succession retention instruments. Nothing is realisable before 2030. The 1,000,000 options and 500,000 restricted stock units granted to each of the two Rales directors are a governance and control matter with no employee read-across at all.
Danaher promotes internal mobility through Danaher Go, and in a federation where salary structures are inherited from acquisitions, a move between operating companies is often the only way to reset a legacy band. That is a career mechanic peers with a single global grade system do not have.
Two labour condition applications sit under the direct Danaher Corporation entity because that entity is a holding and corporate-services company. The filings sit under Cytiva, Leica Biosystems and the other operating companies instead. Concluding that Danaher barely sponsors is a legal-entity artefact, not a hiring policy.
Danaher's own current job postings put sampled director base pay at $160,000 to $250,000 and sampled senior director base pay at $180,000 to $300,000. Those are the only company-published salary ranges in this entire report, and they are the strongest anchor available for a negotiation anywhere on the ladder.
Research control
Against Thermo Fisher, Abbott, Stryker and Agilent, Danaher's 2025 chief executive pay of $23.80 million sits just below Abbott's $24.20 million and above Stryker's $21.40 million and Agilent's $12.83 million, with Thermo Fisher's $79.92 million inflated by a retention award. On the employee side the comparison is harder to make because Danaher publishes no bands, but the structural differences are clear: a lower median employee wage than the technology sector it is often benchmarked against, a materially heavier weighting to stock options than its medtech peers, no disclosed employee share purchase plan, and equity concentrated in leadership rather than spread across the workforce, which is what a 0.42 percent burn rate across 60,000 associates implies.
Evidence classification
| Label | Meaning | Examples and permitted use |
|---|---|---|
| Verified | A Danaher filing, plan document, audited benefit-plan filing, official job posting or government rule. | Executive and board compensation, equity plan terms and reserves, the United States retirement plan, headcount, sales, statutory benefit floors and the director and senior director posted salary ranges. |
| Reported | A named third-party dataset with observable records, chiefly Levels.fyi, Glassdoor, AmbitionBox, Indeed and the visa aggregators. | The United States role anchors behind D3 and D4, the Indian, Australian, German, British, Chinese, Singaporean and Canadian role observations, and the labour condition application wages. |
| Modeled | The Washington, DC anchor multiplied by a level-dependent country and city calibration factor and by the frozen foreign-exchange snapshot, inside a planning envelope. | Every band without a direct posting, every city cell without a direct observation, and all target variable percentages below the officer group. |
| Not publicly disclosed | No source in the research bundle supports a figure, usually because the operating companies hold the information rather than the parent. | Recorded as such throughout rather than estimated, including the rating scale, merit matrix, attrition, city headcount and most non-United States benefit detail. |
Explicit “Not publicly disclosed” index
Known gaps and diligence before relying on a cell
- 1The two named-officer cohorts in the source model, an executive vice president tier and the chief executive tier, are deliberately excluded from the band table and carried in the executive section instead. Both are global corporate roles reported in United States dollars, and leaving them in the ladder would have forced every location factor towards 1.0 at the top and produced absurd offshore executive cells. The employee ladder therefore runs D1 to D10 with seniority 1 to 10.
- 2The source model computed total compensation as base plus target variable plus employer benefit cost plus equity, a loading of roughly 3 to 5 percent at junior levels. That loading is employer cost rather than pay and has been stripped: at D1 to D4, where no equity is evidenced, the total is rebuilt as base plus target variable, and at D5 and above the equity figure is the residual that reconciles to the source total median.
- 3That residual diverges from the disclosed selective grant ranges at D7 and above, where the ranges describe what an actual recipient receives while the band total describes the whole population, most of whom receive nothing. Both figures are shown, and neither should be read as the other.
- 4The source register notes a conflict on the United States 401(k) match: the audited plan filing supports a maximum 4 percent safe-harbor match while some employee-reporting pages show 5 percent. The filed plan governs here, and a 5 percent figure may be specific to one operating company.
- 5Named-officer annual incentive targets other than the chief executive's 200 percent are implied from the disclosed payouts rather than stated as percentages in the bundle, and all five land exactly on a 149.8 percent composite, which is recorded as a finding rather than smoothed away.
- 6The 2025 chief executive summary total is reported as $23,795,280 in the executive tables and the source's own band table shows a $17.7 million to $23.8 million range for the same role, the low end reflecting the incoming chief executive's recurring target architecture rather than an actual payment. Only the disclosed 2025 actual is used in this report.
- 7United States city factors are flat across the ladder because the source calibration applies one city adjustment to the whole curve. That is almost certainly a simplification, but no level-dependent United States city evidence exists in the bundle, so no top-of-ladder factor is invented.
- 8Auckland, Paris, Milan, Copenhagen, Tokyo, Dubai, Zug and Basel carry no Danaher-specific salary observation at all. They are retained because the operating companies do business there, and are marked as regional coverage.
- 9No 2025 or 2026 companywide salary increase, pay freeze, attrition rate or campus-offer policy exists in any reviewed source. The Cepheid and Cytiva reductions are local operating-company actions and should not be generalised.
- 10Only one research bundle exists for Danaher, so no cross-bundle reconciliation was possible and every figure carries that single-source risk.
FX rates used — 1 USD equals, snapshot 2026-08-27
Single-date conversion layer for comparability; it ignores payroll-date FX, tax, purchasing power, benefits valuation and hedging. Compensation intelligence, not legal, tax, investment, immigration or employment advice.
Source register — 17 sources
| S1 | 2025 Form 10-K and Annual Report · Danaher Corporation · Filed February 2026. Sales of $24.568 billion, 60,000 associates, the regional workforce distribution and the operating footprint. |
| S2 | 2026 Proxy Statement on Form DEF 14A · Danaher Corporation · Filed 25 March 2026. 2025 executive compensation, the 343 to 1 pay ratio, incentive design and outcomes, director pay, the equity-plan amendment and the performance share settlement. |
| S3 | 2007 Omnibus Incentive Plan, amended and restated · Danaher Corporation · Approved 5 May 2026. Instrument types, eligibility, the 155,443,592 share reserve, vesting rules and award limits. |
| S4 | Form 8-K on CEO succession and special awards · Danaher Corporation · Filed 3 August 2026. Julie Sawyer Montgomery's terms, the Rainer Blair transition and the August 2026 special equity awards. |
| S5 | Forms 4 and Rule 144 notices · SEC insider filings · 2024 to August 2026. Executive grants, exercises and the 21 August 2026 chief executive share sales. |
| S6 | 2025 United States Savings Plan Form 11-K · Danaher Corporation · Filed June 2026. The 4 percent safe-harbor match, discretionary retirement contributions, vesting and $7.085 billion of plan assets. |
| S7 | Danaher careers site and official job postings · Danaher Corporation · Retrieved August 2026. Published director and senior director salary ranges, role architecture and high-level benefits language. |
| S8 | Danaher compensation pages · Levels.fyi · Retrieved August 2026. Employee-submitted United States role anchors for software engineer, mechanical engineer, product manager, engineering manager and solution architect. |
| S9 | Danaher salary pages by role and geography · Glassdoor · Retrieved August 2026. Observed ranges for scientist, senior scientist and director roles and for the Indian, Australian, German, British, Chinese and Singaporean anchors. |
| S10 | Danaher salary observations · AmbitionBox, Indeed, PayScale, 6figr and Weekday · Retrieved August 2026. India, Canada and United States cross-checks carrying lower evidentiary weight. |
| S11 | Danaher and operating-company labour condition application data · H1BData, H1BGrader and MyVisaJobs · Retrieved August 2026. The two direct-parent wage records and the Cytiva and Leica Biosystems entity averages. |
| S12 | Foreign-exchange reference rates · Federal Reserve H.10, Reserve Bank of Australia and NSE USD/INR quote · 24 to 27 August 2026. The frozen 14-currency conversion table used for every local-currency figure. |
| S13 | Investor releases and public workforce notices · Danaher Corporation and public reporting · 2024 to August 2026. The Masimo acquisition, the Veralto separation, operating-company headcount actions and leadership developments. |
| S14 | 2026 proxy statements · Thermo Fisher, Abbott, Stryker and Agilent · 2026 proxy season. The peer chief executive compensation comparison. |
| S15 | Statutory employment benefits · Australian Taxation Office and Fair Work Ombudsman · Current at 27 August 2026. The 12 percent Superannuation Guarantee and Australian leave floors. |
| S16 | Statutory employment benefits · UK Government and The Pensions Regulator · Current at 27 August 2026. Auto-enrolment pension minimums, holiday entitlement and parental-leave floors. |
| S17 | Statutory employment benefits · EPFO and Indian labour-law sources · Current at 27 August 2026. Provident fund, gratuity and maternity-leave floors. |
Recent News & Workforce Trend
Danaher's 2026 is dominated by a chief executive succession, a large one-time award cycle and portfolio change. No companywide salary action, hike percentage or pay freeze was announced in any reviewed source, and the operating-company reductions below are local rather than enterprise decisions.
Reported headcount is a poor proxy for hiring at Danaher because the portfolio changes underneath it. The 2023 fall is a separation, the 2025 fall mixes local reductions with divestment, and the June 2026 Masimo acquisition adds a population that appears in none of these years. Regional distribution at the end of 2025 was roughly 22,000 in North America, 20,000 in Western Europe, 3,000 in other developed markets and 15,000 in high-growth markets, and no city-level count is disclosed anywhere.
A $1.5 million base salary, a 200 percent target annual cash incentive and a $13.2 million recurring 2027 long-term incentive target, alongside the separate $20 million option award granted in August.
Three same-day tranches of trust-held stock for about $12.74 million, the only open-market insider selling in the reviewed record.
A $20 million option award to the incoming chief executive, $12.5 million to the incoming chief financial officer, $8 million of restricted stock units to the Biotechnology platform head, $2.625 million to the chief science officer, and 1,000,000 options plus 500,000 restricted stock units to each of the two Rales directors. Most option awards vest only in years four and five.
The 8-K set out the incoming chief executive's full pay architecture and the transition arrangements for Rainer Blair, giving the market its first view of the 2027 long-term incentive target.
Adds a new operating-company population and is likely to generate integration retention awards and role-architecture work after the 2025 reporting base.
The omnibus plan authorization rises to 155,443,592 shares and the term extends to 2036. Pro forma overhang moves from 8.30 percent to 10.60 percent.
Chief executive total compensation of $23,795,280 against a $69,440 median employee, a 343 to 1 ratio, a 133 percent company incentive component and a 25 percent settlement on the 2023 to 2025 performance share cycle.
Public reporting described 53 additional positions on top of earlier reductions. This is an operating-company action and does not establish any Danaher-wide pay freeze.
Public notices described about 167 Cepheid roles and 85 Cytiva roles across the year, concentrated in specific sites rather than spread across the group.
The largest single operating-company action in the reviewed record, and a reminder that headcount risk at Danaher is concentrated at the operating company rather than at the parent.
Removes roughly 18,000 associates from the reported base and breaks like-for-like comparison with every earlier headcount, band or pay-ratio figure.